In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds

Antimicrobial Agents and Chemotherapy

Volumn 52, Issue 2, 2008, Pages 761-766

  Goldstein, Ellie J C ^a,b   Citron, Diane M ^a   Merriam, C Vreni ^a   Warren, Yumi A ^a   Tyrrell, Kerin L ^a   Fernandez, Helen T ^a  

^a R M ALDEN RESEARCH LABORATORY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPICILLIN; CARBAPENEM; CLINDAMYCIN; DORIPENEM; ERTAPENEM; IMIPENEM; MEROPENEM; METRONIDAZOLE; PIPERACILLIN PLUS TAZOBACTAM; SULTAMICILLIN;

AEROBIC BACTERIUM; ANAEROBIC BACTERIUM; ARTICLE; BACTERIUM ISOLATION; BACTEROIDES FRAGILIS; CORYNEBACTERIUM; CORYNEBACTERIUM AMYCOLATUM; DIABETIC FOOT; DRUG ACTIVITY; ENTEROBACTER; ESCHERICHIA COLI; HUMAN; IN VITRO STUDY; KLEBSIELLA; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; PROTEUS; PROVIDENCIA; PSEUDOMONAS AERUGINOSA; STREPTOCOCCUS; WOUND INFECTION;

ANTI-BACTERIAL AGENTS; BACTERIA, AEROBIC; BACTERIA, ANAEROBIC; BACTERIAL INFECTIONS; CARBAPENEMS; DIABETIC FOOT; HUMANS; MICROBIAL SENSITIVITY TESTS;

EID: 38649113256     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.01128-07     Document Type: Article

References (19)

1. Anderson, D. L. 2006. Doripenem. Drugs Today 42:399-404.
2. Anonymous. 2003. Doripenem: S 4661. Drugs R. D. 4:363-365.
3. Centers for Disease Control. 2005. National diabetes fact sheet. Centers for Disease Control and Prevention, Atlanta, GA. http://www.cdc.gov/ diabetes/pubs/factsheets.htm.
4. Citron, D. M., E. J. C. Goldstein, C. V. Merriam, B. A. Lipsky, and M. A. Abramson. 2007. Bacteriology of moderate-to-severe diabetic foot infections and in vitro activity of antimicrobial agents. J. Clin. Microbiol. 45:2819-2828.
5. Clinical and Laboratory Standards Institute. 2003. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard, sixth ed. Document M7-A6. CLSI, Wayne, PA.
6. Clinical and Laboratory Standards Institute. 2006. Methods for antimicrobial dilution and disk susceptibility testing of infrequently isolated or fastidious bacteria; approved guidlines. Document M45-A. CLSI, Wayne, PA.
7. Clinical and Laboratory Standards Institute. 2007. Methods for antimicrobial susceptibility testing of anaerobic bacteria; approved standard-sixth ed. Document M11-A7. CLSI, Wayne, PA.
8. Fritsche, T. R., M. G. Stilwell, and R. N. Jones. 2005. Antimicrobial activity of doripenem (S-4661): a global surveillance report (2003). Clin. Microbiol. Infect. 11:974-984.
9. Gerding, D. N. 1995. Foot infections in diabetic patients: the role of anaerobes. Clin. Infect. Dis. 20(Suppl. 2):S283-S288.
10. Goldstein, E. J. C., D. M. Citron, and C. A. Nesbit. 1996. Diabetic foot infections. Bacteriology and activity of 10 oral antimicrobial agents against bacteria isolated from consecutive cases. Diabetes Care 19:638-641.
11. Iso, Y., T. Irie, T. Iwaki, M. Kii, Y. Sendo, K. Motokawa, and Y. Nishitani. 1996. Synthesis and modification of a novel 1-β-methyl carbapenem antibiotic, S-4661. J. Antibiot. 49:478-484.
12. Jones, R. N., H. K. Huynh, and D. J. Biedenbach. 2004. Activities of doripenem (S-4661) against drug-resistant clinical pathogens. Antimicrob. Agents Chemother. 48:3136-3140.
13. Jones, R. N., H. S. Sader, and T. R. Fritsche. 2005. Comparative activity of doripenem and three other carbapenems tested against gram-negative bacilli with various beta-lactamase resistance mechanisms. Diagn. Microbiol. Infect. Dis. 52:71-74.
14. Jousimies-Somer, H. R., P. Summanen, D. M. Citron, E. J. Baron, H. M. Wexler, and S. M. Finegold. 2002. Wadsworth-KTL anaerobic bacteriology manual. Star Publishing, Belmont, CA.
15. Lipsky, B. A., A. R. Berendt, H. G. Deery, J. M. Embil, W. S. Joseph, A. W. Karchmer, J. L. LeFrock, D. P. Lew, J. T. Mader, C. Norden, and J. S. Tan. 2004. Diagnosis and treatment of diabetic foot infections. Clin. Infect. Dis. 39:885-910.
16. Murray, P. R., and E. J. Baron. 2007. Manual of clinical microbiology, vol. 1. ASM Press, Washington, DC.
17. Pumbwe, L., D. Glass, and H. M. Wexler. 2006. Efflux pump overexpression in multiple-antibiotic-resistant mutants of. Antimicrob. Agents Chemother. 50:3150-3153.
18. Sakyo, S., H. Tomita, K. Tanimoto, S. Fujimoto, and Y. Ike. 2006. Potency of carbapenems for the prevention of carbapenem-resistant mutants of Pseudomonas aeruginosa: the high potency of a new carbapenem doripenem. J. Antibiot. 59:220-228.
19. Wexler, H. M., A. E. Engel, D. Glass, and C. Li. 2005. In vitro activities of doripenem and comparator agents against 364 anaerobic clinical isolates. Antimicrob. Agents Chemother. 49:4413-4417.